Glenmark has guided 12-15 per cent revenue growth in FY 18 after a disappointing fourth quarter result which led to 15 per cent fall in stock price in intra day trade on Friday.
The drug maker said it had seen lower than estimated sales of its top selling anti-cholesterol drug Zetia and was also impacted by price erosion in the US market.
At 12 pm, the stock was trading at Rs 782.75.
The company management said it plans to launch 10-15 products including 3-4 products in the US in FY 18 which will drive growth. Also, it said